---
title: "華潤醫藥旗下人凝血因子 IX 獲內地藥物臨牀試驗批准通知書"
description: "華潤醫藥公佈，旗下華潤博雅生物製藥集團收到國家藥品監督管理局頒發的人凝血因子 IX《藥物臨牀試驗批准通知書》。該產品用於凝血因子 IX 缺乏症 (血友病 B) 患者的出血治療。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/276832369.md"
published_at: "2026-02-25T04:29:39.000Z"
---

# 華潤醫藥旗下人凝血因子 IX 獲內地藥物臨牀試驗批准通知書

> 華潤醫藥公佈，旗下華潤博雅生物製藥集團收到國家藥品監督管理局頒發的人凝血因子 IX《藥物臨牀試驗批准通知書》。該產品用於凝血因子 IX 缺乏症 (血友病 B) 患者的出血治療。

華潤醫藥 (03320.HK) 公佈，旗下華潤博雅生物製藥集團收到國家藥品監督管理局頒發的人凝血因子 IX《藥物臨牀試驗批准通知書》。該產品用於凝血因子 IX 缺乏症 (血友病 B) 患者的出血治療。

### Related Stocks

- [588130.CN - 華夏上證科創板生物醫藥ETF](https://longbridge.com/zh-HK/quote/588130.CN.md)
- [159892.CN - 華夏恆生生物科技ETF(QDII)](https://longbridge.com/zh-HK/quote/159892.CN.md)
- [159316.CN - 易方達恆生港股通創新藥ETF](https://longbridge.com/zh-HK/quote/159316.CN.md)
- [300294.CN - 博雅生物](https://longbridge.com/zh-HK/quote/300294.CN.md)
- [520880.CN - 華寶恆生港股通創新藥精選ETF](https://longbridge.com/zh-HK/quote/520880.CN.md)
- [159615.CN - 南方恆生生物科技ETF(QDII)](https://longbridge.com/zh-HK/quote/159615.CN.md)
- [510660.CN - 華夏醫藥ETF](https://longbridge.com/zh-HK/quote/510660.CN.md)
- [589720.CN - 國泰上證科創板創新藥ETF](https://longbridge.com/zh-HK/quote/589720.CN.md)
- [159837.CN - 易方達中證生物科技主題ETF](https://longbridge.com/zh-HK/quote/159837.CN.md)
- [513120.CN - 廣發中證香港創新藥(QDII-ETF)](https://longbridge.com/zh-HK/quote/513120.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | [Link](https://longbridge.com/zh-HK/news/276822785.md) |
| China Medical System Gets China Acceptance for Atopic Dermatitis Drug | China Medical System Gets China Acceptance for Atopic Dermatitis Drug | [Link](https://longbridge.com/zh-HK/news/276718382.md) |
| CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab | CStone Pharmaceuticals has received UK approval for its lung cancer drug, sugemalimab, as a monotherapy for adult patien | [Link](https://longbridge.com/zh-HK/news/276549711.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-HK/news/276035104.md) |
| SinoMab Wins China IND Nod to Expand SM17 Into Inflammatory Bowel Disease | SinoMab Bioscience Ltd. has received approval from China's National Medical Products Administration for an investigation | [Link](https://longbridge.com/zh-HK/news/276765156.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。